histone deacetylase

Type: Keyphrase
Name: histone deacetylase
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

New Findings from Baylor University College of Medicine in the Area of Genetics Reported

By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- Investigators discuss new findings in Genetics. According to news reporting originating in Houston, Texas , by NewsRx journalists, research stated, "The silencing mediator of retinoic ... [Published 4 Traders - Apr 16 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Discovery of the First N-Hydroxycinnamamide-Based Histone Deacetylase 1/3 Dual Inhibitors with Potent Oral Antitumor Activity

† Department of Medicinal Chemistry, School of Pharmacy, Shandong University, Ji’nan, Shandong 250012, P. R. China‡ Department of Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, Medical University of South Carolina, Charleston, ... [Published Journal of Medicinal Chemistry - Apr 15 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Inhibitors of histone deacetylase

This invention comprises the novel compounds of formula (I) wherein n, R1, R2, R3, R4, Q, X, Y, Z and have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing them and their use as a ... [Published Free Patents Online - Apr 15 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of ...

Histone deacetylase (HDAC) inhibitors are a class of agents that have potent antitumor activity with a reported ability to upregulate MHC and costimulatory molecule expression. We hypothesized that epigenetic pharmacological immunomodulation could sensitize ... [Published 7thSpace - Apr 15 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

Cdc4 turns over Hst3 [Genetics]

Ellen R. Edenberg a , Ajay A. Vashisht b , Benjamin R. Topacio a , James A. Wohlschlegel b , and David P. Toczyski a , 1 a Department of Biochemistry and Biophysics, University of California, San Francisco, CA 94158; and b Department of Biological ... [Published PNAS - Apr 08 2014]
First reported Apr 04 2014 - Updated Apr 04 2014 - 1 reports

Epigenetic inheritance

in DNA, RNA, Epigenetics Research , North AmericaEpigenetics has become an area of growing interest as research uncovers the extent to which it plays a role in health and diseases. It’s of particular interest for many as diseases such as cancer have been ... [Published BioScreening - Apr 04 2014]
First reported Apr 01 2014 - Updated Apr 01 2014 - 1 reports

Histone deacetylase inhibitors based simultaneously on trisubstituted 1H-pyrroles and aromatic and heteroaromatic spacers

The present invention refers to compounds derived from trisubstituted 1H-pyrrole rings and aromatic rings, which have the following formula (I): wherein: R1 and R2 represent, independently, an optionally substituted C6-C10 aryl radical or an optionally ... [Published Free Patents Online - Apr 01 2014]
First reported Apr 01 2014 - Updated Apr 01 2014 - 1 reports

Enzyme inhibitors

Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers ... [Published Free Patents Online - Apr 01 2014]
First reported Apr 01 2014 - Updated Apr 01 2014 - 1 reports

Spirocyclic compounds

The present invention relates to a novel class of substituted spirocyclic compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis ... [Published Free Patents Online - Apr 01 2014]
First reported Mar 29 2014 - Updated Mar 29 2014 - 1 reports

3/28/14 - Taiwan Province of China,United States : TAIWAN cancer drug gets approval from FDA for clinical trials [TendersInfo (India)]

A Taiwan-developed anti-cancer drug was greenlighted by the US Food and Drug Administration (FDA) for phase 1 of human clinical trials.MPT0E028, a potent histone deacetylase inhibitor, is showing promising results in the treatment of cancer with test ... [Published Pharmacy Choice - Mar 29 2014]
First reported Mar 28 2014 - Updated Mar 28 2014 - 1 reports

Acetylon Pharmaceuticals Celebrates Headquarters Expansion in Boston's Innovation District

(NewsRx) -- By a News Reporter-Staff News Editor at Biotech Business Week -- Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, announced the expansion of ... [Published NewsRX - Mar 28 2014]
First reported Mar 20 2014 - Updated Mar 20 2014 - 1 reports

Acetylon Pharmaceuticals Celebrates Headquarters Expansion In Boston???s Innovation District

BOSTON--(BUSINESS WIRE)--Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, today announced the expansion of its headquarters facility located in Boston’s ... [Published BioSpace - Mar 20 2014]

Quotes

Anders Vadsholt, CEO of Topotarget, said: "The positioning of BioAlliance Pharma, their late stage assets and expertise makes BioAlliance Pharma a perfect fit as a company to merge with, allowing the acceleration of belinostat development in several new orphan oncology indications by leveraging on both team's synergistic expertise. We are confident that this merger will deliver to our shareholders the best possible value and the opportunity to jointly shape a dynamic new player in the orphan oncology market."
...According to news reporting out of Seoul, South Korea, by NewsRx editors, research stated, "Metastasis-associated protein 1 (MTA1) is a component of the nucleosome remodeling and histone deacetylase (HDAC) complex, which plays an important role in progression of breast cancer. Although MTA1 is known as a repressor of the transactivation function of estrogen receptor alpha (ER alpha), its involvement in the epigenetic control of transcription of the ER alpha gene ESR1 has not been studied."
...a supplement to the background information on this patent, NewsRx correspondents also obtained the inventors' summary information for this patent: "The present invention is based on the recognition that the published procedures for isolating romidepsin do not reproducibly yield pure romidepsin, in particular, romidepsin free of contaminants such as dimerized, oligomerized, or polymerized romidepsin. Based on this recognition, the present invention provides a system for reproducibly preparing romidepsin under conditions that reduce the levels of these contaminating side products. Producing, purifying, and/or storing romidepsin at an apparent pH less than approximately 6.5, more preferably less than approximately 6.0, has been found to prevent the formation of dimerized, oligomerized, or polymerized romidepsin. This improvement in the purification process of romidepsin allows for higher yields of romidepsin and/or higher purity romidepsin than that provided by known processes. Such an improvement is particularly useful for preparing pharmaceutical grade romidepsin for use in humans."
According to the news reporters, the research concluded: "Collectively, these data highlight a biological role for SMRT in mediating DNA damage responses and suggest a model where p53 binding to the DAD limits HDAC3 interaction with this coregulator, thereby facilitating SMRT coactivation of p53-dependent gene expression."

More Content

All (87) | News (83) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (3)
sort by: Date | Relevance
BioAlliance Pharma, Topotarget to merge to crea... [Published PharmaBiz - Apr 18 2014]
BioAlliance Pharma and Topotarget to Merge [Published Individual.com - Apr 18 2014]
New Findings from Seoul National University in ... [Published NewsRX - Apr 18 2014]
Celgene : Patent Issued for Preparation of Romi... [Published 4 Traders - Apr 17 2014]
BioAlliance Pharma, Topotarget to merge [Published Center Watch - Apr 17 2014]
New Findings from Baylor University College of ... [Published 4 Traders - Apr 16 2014]
Quantitative Trait Loci (QTL) Study Identifies ... [Published PLoS medicine - Apr 16 2014]
BioAlliance and Topotarget merge to focus on ra... [Published PMLive - Apr 16 2014]
BioAlliance Pharma and Topotarget merge to crea... [Published Pharma Letter - Apr 16 2014]
BioAlliance Pharma and Topotarget Announce Merg... [Published PharmaceuticalProcessing - Apr 16 2014]
BioAlliance Pharma to merge with Topotarget [Published Manufacturing Chemist - Apr 16 2014]
Stress Makes the Clock Tick [Published PLoS Biology - Apr 16 2014]
Discovery of the First N-Hydroxycinnamamide-Bas... [Published Journal of Medicinal Chemistry - Apr 15 2014]
Inhibitors of histone deacetylase [Published Free Patents Online - Apr 15 2014]
The histone deacetylase inhibitor, LBH589, prom... [Published 7thSpace - Apr 15 2014]
Oncology: Researchers at Mackay Memorial Hospit... [Published NewsRX - Apr 15 2014]
Regenerating muscle in Duchenne muscular dystro... [Published Health Canal - Apr 14 2014]
Aiming to defeat HIV [Published Drug Discovery News - Apr 12 2014]
GSK-3β and Vitamin D Receptor are Involved in β... [Published Sexual Development - Apr 12 2014]
New Findings from Karolinska Institute Describe... [Published HispanicBusiness.com - Apr 10 2014]
Cdc4 turns over Hst3 [Genetics] [Published PNAS - Apr 08 2014]
MEI Pharma Adds Former VC David Urso as Senior ... [Published FinanzNachrichten.de - Apr 08 2014]
MEI Pharma Identifies Potential Biomarker For P... [Published FinanzNachrichten.de - Apr 07 2014]
Epigenetic inheritance [Published BioScreening - Apr 04 2014]
Epigenetic Mechanisms in the Pathogenesis of Di... [Published Sexual Development - Apr 03 2014]
Patent Issued for Host Cells Comprising Alpha 1... [Published 4 Traders - Apr 03 2014]
Gene silencing instructions acquired through 'm... [Published HispanicBusiness.com - Apr 02 2014]
Effect of two series of isoindolines over HDAC8... [Published Springer Link Journal - Apr 02 2014]
Curis to Present at the 13th Annual Needham Hea... [Published Benzinga.com - Apr 02 2014]
Endostem making real progress in treatments for... [Published Cordis - Apr 02 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
DOTW Keeps Tabs As Tax Trimming Fuels Deals [Published The IN VIVO Blog - Feb 28 2014]
As an industry, biopharma actually fares pretty well when it comes to taxes. Among profitable companies, biotech and pharma have some of the lowest effective U.S. tax rates compared to companies in other sectors. But that doesn’t mean they have stopped ...
1

Press Releases

sort by: Date | Relevance
Repligen Announces Asset Purchase Agreement Wit... [Published GlobeNewswire: Acquisitions News - Jan 21 2014]
BioMarin Announces Agreement With Repligen for ... [Published GlobeNewswire: Acquisitions News - Jan 21 2014]
Mirati Therapeutics to Present at the 25th Annu... [Published PR Newswire - Nov 22 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.